| First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial YY Janjigian, SB Maron, WK Chatila, B Millang, SS Chavan, C Alterman, ... The Lancet Oncology 21 (6), 821-831, 2020 | 299 | 2020 |
| Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma E Pectasides, MD Stachler, S Derks, Y Liu, S Maron, M Islam, L Alpert, ... Cancer discovery 8 (1), 37-48, 2018 | 274 | 2018 |
| Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma SB Maron, LM Chase, S Lomnicki, S Kochanny, KL Moore, SS Joshi, ... Clinical cancer research 25 (23), 7098-7112, 2019 | 164 | 2019 |
| The spectrum of benefit from checkpoint blockade in hypermutated tumors B Rousseau, MB Foote, SB Maron, BH Diplas, S Lu, G Argilés, A Cercek, ... New England Journal of Medicine 384 (12), 1168-1170, 2021 | 158 | 2021 |
| Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma SB Maron, L Alpert, HA Kwak, S Lomnicki, L Chase, D Xu, E O'Day, ... Cancer discovery 8 (6), 696-713, 2018 | 111 | 2018 |
| Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma SS Joshi, SB Maron, DV Catenacci Future oncology 14 (5), 417-430, 2018 | 78 | 2018 |
| Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results CD Palmer, AR Rappaport, MJ Davis, MG Hart, CD Scallan, SJ Hong, ... Nature medicine 28 (8), 1619-1629, 2022 | 77 | 2022 |
| OncoTree: a cancer classification system for precision oncology R Kundra, H Zhang, R Sheridan, SJ Sirintrapun, A Wang, A Ochoa, ... JCO clinical cancer informatics 5, 221-230, 2021 | 69 | 2021 |
| First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma YY Janjigian, S Maron, JF Chou, AR Gabler, MZ Simmons, P Momtaz, ... Annals of Oncology 30, v313, 2019 | 66 | 2019 |
| Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma. Cancer Discov. 2018; 8: 37–48. doi: 10.1158/2159-8290 E Pectasides, MD Stachler, S Derks, Y Liu, S Maron, M Islam, L Alpert, ... CD-17-0395.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 40 | |
| Lineage specific recombination and positive selection in coding and intragenic regions contributed to evolution of the main Listeria monocytogenes virulence gene cluster RH Orsi, SB Maron, KK Nightingale, M Jerome, H Tabor, M Wiedmann Infection, Genetics and Evolution 8 (5), 566-576, 2008 | 34 | 2008 |
| Initial report of second‐line FOLFIRI in combination with ramucirumab in advanced gastroesophageal adenocarcinomas: A multi‐institutional retrospective analysis SJ Klempner, SB Maron, L Chase, S Lomnicki, ZA Wainberg, ... The oncologist 24 (4), 475-482, 2019 | 33 | 2019 |
| PD-1 blockade in solid tumors with defects in polymerase epsilon B Rousseau, I Bieche, E Pasmant, N Hamzaoui, N Leulliot, L Michon, ... Cancer discovery 12 (6), 1435-1448, 2022 | 31 | 2022 |
| Analysis of circulating tumor DNA to predict risk of recurrence in patients with esophageal and gastric cancers BM Huffman, VN Aushev, GL Budde, J Chao, F Dayyani, D Hanna, ... JCO Precision Oncology 6, e2200420, 2022 | 28 | 2022 |
| Evaluation of the association of perioperative UGT1A1 genotype–dosed gFOLFIRINOX with margin-negative resection rates and pathologic response grades among patients with locally … DVT Catenacci, L Chase, S Lomnicki, T Karrison, R de Wilton Marsh, ... JAMA Network Open 3 (2), e1921290-e1921290, 2020 | 27 | 2020 |
| Obstruction predicts worse long-term outcomes in stage III colon cancer: a secondary analysis of the N0147 trial FS Dahdaleh, SK Sherman, EC Poli, J Vigneswaran, BN Polite, ... Surgery 164 (6), 1223-1229, 2018 | 24 | 2018 |
| Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis. SB Maron, WK Chatila, BM Millang, S Sabwa, JF Chou, L Ling, R Nagy, ... Journal of Clinical Oncology 38 (15_suppl), 4559-4559, 2020 | 23 | 2020 |
| Novel targeted therapies for esophagogastric cancer SB Maron, DVT Catenacci Surgical Oncology Clinics 26 (2), 293-312, 2017 | 22 | 2017 |
| Obtaining knowledge in pathology reports through a natural language processing approach with classification, named-entity recognition, and relation-extraction heuristics T Oliwa, SB Maron, LM Chase, S Lomnicki, DVT Catenacci, B Furner, ... JCO clinical cancer informatics 3, 1-8, 2019 | 21 | 2019 |
| FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape SJ Klempner, R Madison, V Pujara, JS Ross, VA Miller, SM Ali, ... The Oncologist 24 (11), 1462-1468, 2019 | 20 | 2019 |
